| Literature DB >> 31324563 |
Alexander B Draganov1, Xiaoxiao Yang1, Abiodun Anifowose1, Ladie Kimberly C De La Cruz1, Chaofeng Dai1, Nanting Ni1, Weixuan Chen1, Zeus De Los Santos1, Lubing Gu2, Muxiang Zhou2, Binghe Wang3.
Abstract
In a previous study, a novel anthraquinone analog BW-AQ-101 was identified as a potent inducer of MDM2 degradation, leading to upregulation of p53 and apoptosis in cell culture studies. In animal models of acute lymphocytic leukemia, treatment with BW-AQ-101 led to complete disease remission. In this study, we systematically investigated the effect of substitution patterns of the core anthraquinone scaffold. Through cytotoxicity evaluation in two leukemia cell lines, the structure-activity relationship of thirty-two analogs has been examined. Several analogs with comparable or improved potency over BW-AQ-101 have been identified. Western-blot assays verified the effect of the potent compounds on the MDM2-p53 axis. The study also suggests new chemical space for further optimization work.Entities:
Keywords: Anthraquinone; Anti-tumor activity; Lymphoblastic leukemia; MDM2 inhibitor; p53 activation
Year: 2019 PMID: 31324563 DOI: 10.1016/j.bmc.2019.07.019
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641